Drug Trial Radar · NCT06864130
A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,400
Planned (sponsor's estimate)
Start
Feb 21, 2025
Primary completion
Mar 1, 2029
Study completion Sep 15, 2029
Sponsor
- Lead sponsor
- Odense University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to study the effects of discontinuation of Alendronate treatment for three years. The participants are postmenopausal women with osteoporosis, who have had a treatment period without fractures. The study will answer: * What is the rate of fragility fractures during the study? The hypothesis is that discontinuation of Alendronate after a fracture-free period does not raise the 3-year fracture risk. * Are there predictors of significant bone loss after discontinuation of Alendronate? The hypothesis is that clinical, biochemical, cellular, or molecular characteristics can predict bone loss. Researchers will compare the outcomes of discontinuation of Alendronate with continuing treatment. Participants will be randomly assigned to a group. Participants will: * Either take alendronate once weekly for three years OR discontinue their treatment * Visit the clinic at 6 and 18 months for blood samples * Visit the clinic at the start of the study and after 1, 2, and 3 years for bone scans and blood samples.
Conditions
- Osteoporosis in Post-menopausal Women
Interventions
Alendronate 70mg weeklyDrug
The intervention is discontinuation of Alendronate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Fragility fracturesTime frame: From enrollment to the end of the 3 year study period.
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Aalborg University Hospital
Aalborg, Denmark · Not yet recruiting
Bispebjerg Hospital
Copenhagen, Denmark · Not yet recruiting
Esbjerg Og Grindsted Sygehus
Esbjerg, Denmark · Recruiting
Copenhagen University Hospital (Herlev)
Herlev, Denmark · Recruiting
Nordsjaellands Hospital (Hillerød)
Hillerød, Denmark · Recruiting
Hvidovre Hospital
Hvidovre, Denmark · Not yet recruiting
Odense University Hospital
Odense, Denmark · Recruiting
Sygehus Sønderjylland, Tønder
Tønder, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.